Ose Immunotherapeutics

Ose Immunotherapeutics company information, Employees & Contact Information

OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis). • Anti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024. • ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. 4 proprietary drug discovery platforms • Pro-resolutive mAb platform • Myeloid Checkpoint platform • BiCKI® Platform • mRNA Therapeutic platform f

Company Details

Employees
82
Founded
-
Address
22, Avenue Bénoni Goullin, Nantes,pays De La Loire 44200,france
Phone
33143297857
Email
co****@****uno.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
NANTES, PAYS DE LA LOIRE
Looking for a particular Ose Immunotherapeutics employee's phone or email?

Ose Immunotherapeutics Questions

News

OSE Immunotherapeutics Reports First Half 2025 Financial Results - GlobeNewswire

OSE Immunotherapeutics Reports First Half 2025 Financial Results GlobeNewswire

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025 - Yahoo Finance

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025 Yahoo Finance

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors - GlobeNewswire

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors GlobeNewswire

OSE Immunotherapeutics Publishes Letter to Shareholders - Yahoo Finance

OSE Immunotherapeutics Publishes Letter to Shareholders Yahoo Finance

OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025 - Yahoo Finance

OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025 Yahoo Finance

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court - GlobeNewswire

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court GlobeNewswire

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer - Yahoo Finance

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer Yahoo Finance

OSE Immunotherapeutics, Inserm Transfert and Nantes - GlobeNewswire

OSE Immunotherapeutics, Inserm Transfert and Nantes GlobeNewswire

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology - GlobeNewswire

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology GlobeNewswire

OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels - Yahoo! Finance UK

OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels Yahoo! Finance UK

Update on Information Relating to the General Meeting of September 30, 2025 - GlobeNewswire

Update on Information Relating to the General Meeting of September 30, 2025 GlobeNewswire

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation - Yahoo! Finance UK

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation Yahoo! Finance UK

Two International Proxy Advisory Firms Support the - GlobeNewswire

Two International Proxy Advisory Firms Support the GlobeNewswire

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer - Yahoo Finance

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer Yahoo Finance

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer - GlobeNewswire

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer GlobeNewswire

OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies - GlobeNewswire

OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies GlobeNewswire

ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025 - GlobeNewswire

ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025 GlobeNewswire

OSE Immunotherapeutics Reaffirms its Strategic Priorities - GlobeNewswire

OSE Immunotherapeutics Reaffirms its Strategic Priorities GlobeNewswire

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025 - GlobeNewswire

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025 GlobeNewswire

Appointment of Marc Le Bozec as Interim CEO - GlobeNewswire

Appointment of Marc Le Bozec as Interim CEO GlobeNewswire

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update GlobeNewswire

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting - Yahoo! Finance UK

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting Yahoo! Finance UK

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital - GlobeNewswire

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital GlobeNewswire

OSE Immunotherapeutics and Scienta Lab Establish Strategic - GlobeNewswire

OSE Immunotherapeutics and Scienta Lab Establish Strategic GlobeNewswire

OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer - Yahoo Finance

OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer Yahoo Finance

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update - Yahoo! Finance UK

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Yahoo! Finance UK

OSE Immunotherapeutics and Boehringer Ingelheim expand - GlobeNewswire

OSE Immunotherapeutics and Boehringer Ingelheim expand GlobeNewswire

OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics - Business Wire

OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics Business Wire

OSE Immunotherapeutics Provides Positive Long Term Memory - GlobeNewswire

OSE Immunotherapeutics Provides Positive Long Term Memory GlobeNewswire

OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer - Business Wire

OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer Business Wire

OSE Immunotherapeutics Receives a Grant From French - GlobeNewswire

OSE Immunotherapeutics Receives a Grant From French GlobeNewswire

Top Ose Immunotherapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant